AstraZeneca announced plans to cut 8,000 jobs — around 12% of its global workforce — by 2014 as part of a cost-cutting exercise. The firm, which has already eliminated 12,600 jobs in recent years, will lose US market exclusivity on Arimidex and Pulmicort Respules this year and has projected a revenue decline in the mid-single digits for the year. The company will also restructure its R&D function to focus on fewer disease area targets and close some R&D sites.
Company News: AstraZeneca
AstraZeneca announced plans to cut 8,000 jobs -- around 12% of its global workforce -- by 2014 as part of a cost-cutting exercise. The firm, which has already eliminated 12,600 jobs in recent years, will lose US market exclusivity on Arimidex and Pulmicort Respules this year and has projected a revenue decline in the mid-single digits for the year. The company will also restructure its R&D function to focus on fewer disease area targets and close some R&D sites.
